ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in upcoming investor conferences.
- LEERINK Partners 6th Annual Global Healthcare Conference, February 15-16, 2017, New York
- 2017 Disruptive Growth & Healthcare Conference, February 15, 2017, New York
- RBC Capital Markets 2017 Global Healthcare Conference, February 22-23, 2017, New York
Arbutus’ President and CEO, Dr. Mark J. Murray, will participate in a fireside chat at the LEERINK conference on February 16, 2017. A simultaneous webcast can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations. Replays will be available on the Arbutus website following the event.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Helia Baradarani Senior Manager, Investor Relations Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
